Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

Discloses “Going Concern” Explanatory Paragraph in Auditor's Report Discloses “Going Concern” Explanatory Paragraph in Auditor's Report

BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

Initiative marks entry into Israel's rapidly growing autonomous AI defense, firefighting and first response activities Initiative marks entry into Israel's rapidly growing autonomous AI defense, firefighting and first response activities

BiomX CEO Issues Letter to Stockholders

CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities DOVER, Del., March 19, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE), today released the following letter from its Chief Executive Officer to stockholders.

BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

Seasoned financial leaders join BiomX to support strategic execution and advancement of the company DOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer.